NASDAQ:COLL
Collegium Pharmaceutical Stock News
$32.47
-1.20 (-3.56%)
At Close: May 17, 2024
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates
07:46pm, Thursday, 05'th Aug 2021
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stoc
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
04:47pm, Thursday, 29'th Jul 2021
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
04:01pm, Wednesday, 21'st Jul 2021
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2
Collegium Pharmaceutical: Moving Closer To The Top
08:42am, Monday, 12'th Jul 2021
Collegium Pharmaceutical: Moving Closer To The Top
Collegium Announces Publication of Real-World Data in Journal of Pain Research
04:01pm, Wednesday, 16'th Jun 2021
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis
01:00pm, Wednesday, 02'nd Jun 2021
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Collegium to Participate in Upcoming Investor Conference
04:05pm, Thursday, 20'th May 2021
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2021 Results - Earnings Call Transcript
01:58am, Sunday, 09'th May 2021
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2021 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates
07:32pm, Thursday, 06'th May 2021
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
04:01pm, Thursday, 15'th Apr 2021
STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May
Collegium Pharmaceutical: No Longer Speculative After A Year Of Profitability
01:08pm, Thursday, 04'th Mar 2021
Despite the COVID -19 pandemic, Collegium Pharmaceutical had an impressive 2020. The company recorded a full year of profitability and commercial progress. Collegium is off to a good start in 2021, wi
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2020 Results - Earnings Call Transcript
04:53pm, Saturday, 27'th Feb 2021
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2020 Results - Earnings Call Transcript
Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
04:01pm, Thursday, 11'th Feb 2021
STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Febru
Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday
06:31pm, Tuesday, 09'th Feb 2021
It's not every day that a company graduates to a slot in a high-profile stock index.
Collegium Provides 2021 Financial Guidance
04:01pm, Wednesday, 06'th Jan 2021
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –
